玻璃体内注射甲氨蝶呤治疗原发性眼内淋巴瘤
Treatment of primary intraocular lymphoma with intravitreal methotrexate.
作者信息
Sou Reika, Ohguro Nobuyuki, Maeda Tetsuo, Saishin Yoshitsugu, Tano Yasuo
机构信息
Department of Ophthalmology, Osaka University Medical School, Osaka, Japan.
Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
出版信息
Jpn J Ophthalmol. 2008 May-Jun;52(3):167-174. doi: 10.1007/s10384-008-0519-9. Epub 2008 Jul 27.
PURPOSE
To report the efficacy of intravitreal chemotherapy for primary intraocular lymphoma (PIOL).
METHODS
Retrospective, noncomparative interventional case reports are presented for six patients (ten eyes; mean age, 58.8 years) with pathologically confirmed PIOL who participated in this study and were treated at our hospital with intravitreal injections of methotrexate (MTX) between January 2004 and February 2007. Intravitreal injections of MTX (400 microg MTX/50 microl Opeguard-MA) were administered once or twice weekly for 1 month followed by ten monthly injections. Interleukin-10 (IL-10) and IL-6 were measured in the vitreous before and after injections to determine tumor activity.
RESULTS
All eyes were clinically cleared of malignant cells. One eye lost vision. After intravitreal chemotherapy, the vitreous IL-10 concentration reached barely detectable levels.
CONCLUSIONS
Intravitreal chemotherapy achieves clinical remission and preserves vision in patients with PIOL.
目的
报告玻璃体内化疗治疗原发性眼内淋巴瘤（PIOL）的疗效。
方法
对6例（10只眼；平均年龄58.8岁）经病理证实为PIOL且参与本研究的患者进行回顾性、非对比性介入病例报告，这些患者于2004年1月至2007年2月在我院接受玻璃体内注射甲氨蝶呤（MTX）治疗。玻璃体内注射MTX（400微克MTX/50微升Opeguard-MA）每周给药1次或2次，持续1个月，随后每月注射1次，共10次。在注射前后测量玻璃体中的白细胞介素-10（IL-10）和白细胞介素-6，以确定肿瘤活性。
结果
所有患眼临床恶性细胞均清除。1只眼失明。玻璃体内化疗后，玻璃体IL-10浓度降至几乎检测不到的水平。
结论
玻璃体内化疗可使PIOL患者获得临床缓解并保留视力。
Zotero 插件